Evaluation of in vitro and in vivo antitumor activity of BCNU-Ioaded PLGA wafer against 9L gliosarcoma

The purpose of the present study was to develop implantable BCNU-Ioaded poly(D,L-lactide-co-glycolide) (PLGA) wafer for the controlled release of 1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU) and to evaluate its in vitro and in vivo antitumor activity. The release rate of BCNU from PLGA wafer increased with the increase of BCNU amount loaded and the release was continued until 7 days. In vitro and in vivo antitumor activity of BCNU-Ioaded PLGA wafer was investigated using in vitro cytotoxicity against 9L gliosarcoma cells and a subcutaneous (s.c.) solid tumor model of 9L gliosarcoma, respectively. The wafers containing BCNU showed more effective cytotoxicity than BCNU powder due to its short half-life and inhibited the proliferation of 9L gliosarcoma cells. BCNU-Ioaded PLGA wafer delayed the growth of the tumors significantly and increasing the dose of BCNU in the wafer resulted in a Substantial regression of the tumor. These results of antitumor activity of BCNU-Ioaded PLGA wafer demonstrate the feasibility of the wafers for clinical application. (C) 2004 Elsevier B.V. All rights reserved.